INTRODUCTION
In the neonatal intensive care setting, cisapride, a benzamide, has been widely used as a prokinetic agent in the treatment of gastrointestinal motility disorders including gastroesophageal reflux, postoperative ileus, and dysmotility associated with gastroschisis or omphalocele. 1 -6 The immaturity of gastrointestinal function in the very premature infant often precludes optimal nutrition by the enteral route. The development of adequate gastrointestinal motor function (requiring the maturation of enteric nerves, endocrine cells, and smooth muscle cells) lags many weeks behind the absorptive and digestive development. 7, 8 Thus, those premature infants whose nutritional needs are greatest may be disadvantaged primarily because of the inherent dysmotility present throughout the gastrointestinal system. Nutritional deprivation at this critical and vulnerable period of the infant's life may severely compromise brain growth to produce serious deficits in learning, memory, and behavior. Additionally, poor gastric and intestinal motor activity compounded by gastroesophageal reflux may explain feeding intolerance in many infants.
Given that the prokinetic action of cisapride extends to the entire gastrointestinal tract, it may be particularly useful in premature infants who have a higher incidence of hypomotility problems. 9 -12 Cisapride has therefore been used in both preterm and term infants with feeding intolerance, postoperative ileus, and other related conditions where gastrointestinal dysmotility poses a problem. 2, 13 In studies involving adults and children, some patients receiving cisapride have shown an increase in the QT interval on the electrocardiogram (ECG). 14, 15 A similar lengthening of the QT interval has been reported in infants receiving cisapride. 16 -19 However, a separate study did not find significant prolongation of the QT interval or other related adverse effects in infants receiving cisapride. 20 By delaying cardiac repolarization (as evidenced by a prolonged QT interval), cisapride also increases the risk for developing severe arrhythmias and their serious sequelae. 14 -16,21,22 A wide variety of cisapride dosages have been used in these studies.
Cisapride was removed from the market in March of 2000 primarily based on morbidities and mortalities reported in adults who were receiving either arrhythmogenic drugs or medications that inhibit the cytochrome P-450 3A4 enzyme system. Concerns regarding the cardiac safety of cisapride given to infants led to our study. We asked what is the effect of a standard dose of cisapride on the corrected QT (QTc) interval during the first 14 days of administration.
METHODS

Study Design
All infants (irrespective of gestational age) receiving cisapride as part of their clinical management in our neonatal intensive care unit
OBJECTIVE:
To examine the effect of cisapride on the corrected QT ( QTc ) interval in infants over a 14 -day period.
STUDY DESIGN:
A prospective cohort study of infants receiving cisapride ( 0.8 mg / kg per day ). Twelve -lead electrocardiograms were obtained before and 3, 5, 7, and 14 days after cisapride initiation.
RESULTS:
Fifty infants completed the study; none had arrhythmias. Fifteen of 50 infants ( 30% ) developed QTc interval 450 msec; QTc interval normalized in 13 of 15 infants. Infants with QTc interval on day 3 2 standard deviations above the mean baseline QTc interval ( 401 + 40 msec ) were more likely to develop prolonged QTc interval ( p < 0.0001 ).
CONCLUSION:
QTc interval prolongation was noted in 30% of infants. Subsequently, the majority of those infants had QTc interval normalization by day 14 Original Article
were eligible for this prospective cohort study. Infants were excluded if they had a QTc interval 470 msec (strongly indicative of long QT syndrome) before the start of cisapride therapy. 23 
Variables and Clinical Monitoring
Demographic and clinical data obtained for each infant included: gestational age, postnatal age, postconceptional age (defined as gestational age plus the postnatal age) at the time of cisapride introduction, birth weight, gender, Apgar scores, and the concomitant use of medications that inhibit the cytochrome P-450 3A4 enzyme system. 24 -26 Data obtained from routine laboratory investigations for liver function, serum electrolytes, and serum calcium were also recorded. Each infant had continuous cardiopulmonary monitoring throughout the study period.
Drug Dosage
Infants received a standard therapeutic dose of cisapride (0.8 mg/kg per day, administered enterally every 6 hours) as recommended by the North American Society for Pediatric Gastroenterology and Nutrition. 16, 18, 20, 24 QTc Protocol A 12-lead ECG was obtained from each infant before starting cisapride, and on days 3, 5, 7, and 14 following the start of cisapride administration. ECGs were obtained, QT intervals measured, and QTc intervals calculated by a single investigator. ECGs were obtained using a Hewlett-Packard page writer, XL1 (Model # M1700A). The QT interval (the period from the start of depolarization, QRS complex, to the end of repolarization, T wave, of the ventricles) was measured in either lead II or lead V5. The QTc interval was calculated using Bazett's formula. 27 A pediatric cardiologist subsequently confirmed the QT interval measurements and the QTc interval calculations. We defined a QTc interval 450 msec as prolonged. 16, 17, 28, 29 The infant's attending neonatologist was informed when the QTc interval was prolonged. The neonatologist then made a clinical decision to continue or discontinue cisapride. Follow-up ECGs were obtained even if cisapride was discontinued before the completion of the 14 days of data collection.
Our Institutional Review Board approved this study. Informed written consent was obtained from parents before enrollment of infants into the study.
Statistical Analysis
Descriptive statistics were used to analyze clinical and demographic variables. Infants were stratified into gestational and postconceptional age groups. We compared the QTc interval at the various time points with an analysis of variance for repeated measures with gestational and postconceptional ages as covariates.
All data are presented as mean±standard deviation (SD). Statistical analysis was performed using a standard commercial software package (SPSS version 10.0, SPSS Inc., Chicago, IL). A p value of <0.05 was considered statistically significant.
RESULTS
Sixty infants were enrolled in the study between April and September 1998, 8 were discharged from the hospital before completing the study, and cisapride was discontinued in 2 infants by the attending neonatologist for lack of clinical improvement. Of the 50 infants who completed the study, 44 were preterm and 6 term. Indications for cisapride treatment included feeding intolerance, apnea and bradycardia episodes secondary to gastroesophageal reflux, and gastrointestinal dysmotility. The mean gestational age of the infants was 29.9 weeks with a mean age at cisapride initiation of 34.5 weeks postconceptional age (Table 1) .
All infants had normal alanine aminotransferase and aspartate aminotransferase values. Although some infants received diuretic drugs and salt supplementation, they all had normal serum electrolytes and ionized calcium. There was no difference in serum albumin levels when comparing infants who had a prolonged QTc interval and infants with normal QTc interval. No infants received concomitant medications known to inhibit cytochrome P-450 3A4 enzyme systems. No infants had clinical deterioration, adverse events or cardiac arrhythmias during the study.
Fifteen of 50 infants (30%) developed a prolonged QTc interval at some time during the 14-day study period (Table 2 ). There was no Data presented as mean ± 1 SD. *Postconceptional age ( PCA, weeks ) = gestational age + postnatal age.
correlation between gestational age and the development of prolonged QTc interval. There was a weak correlation between postconceptional age at initiation of cisapride and the development of prolonged QTc interval (r=0.285, p=0.045). Of the 15 infants who developed prolonged QTc interval, 5 had cisapride discontinued during the study period by their attending neonatologist. The maximum QTc interval recorded in these 5 infants was 506 msec. The remaining 10 infants with prolonged QTc interval continued to receive cisapride during the study period. The highest recorded QTc interval in these 10 infants was 491 msec. The QTc interval normalized in 13 of the 15 infants who at some point developed prolonged QTc interval. The overall mean baseline QTc interval was 401±20 msec. The 15 infants who developed prolonged QTc interval had statistically longer QTc intervals at baseline and days 3, 5, 7, and 14 of the study compared to the 35 infants who maintained normal QTc interval (Figure 1) .
We wished to identify a predictor of infants who would develop prolonged QTc interval. We initially asked whether a prolonged QTc interval could be predicted by an abnormal baseline QTc interval. There was a weak correlation between baseline QTc interval (QTc0) and subsequent prolonged QTc interval (0.350, p=0.013). We asked whether having a QTc0>2 SD greater than the mean QTc0 (441 msec) would predict subsequent prolonged QTc interval. Of the 15 infants who had prolonged QTc interval, only 2 had a QTc0 >441 msec. Conversely, of the 35 infants who never had a prolonged QTc interval, none had a QTc0 >441 msec. Therefore, a QTc0 >441 msec has a sensitivity of 0.13 and a specificity of 1.0 and was not predictive of prolonged QTc interval.
We then asked whether having a QTc interval >441 msec at any subsequent study time point would predict prolonged QTc interval. There was a correlation between the presence of prolonged QTc Figure 1 . QTc interval at baseline, 3, 5, 7, and 14 days of cisapride in infants with normal versus prolonged QTc interval. 
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QTc Interval in Infants Receiving Cisapride interval and QTc interval >441 msec on days 3, 5, 7, and 14. The best correlation between the presence of prolonged QTc interval and QTc interval >441 msec was at day 3 (QTc3) (r=0.624, p<0.0001). Of the 15 infants who had prolonged QTc interval, 11 had a QTc3 >441 msec. Of the 35 infants who never had prolonged QTc interval, only 4 had a QTc3 >441 msec. Therefore, a QTc3 >441 msec has a sensitivity of 0.73, specificity of 0.89, a positive predictive value of 0.71, and a negative predictive value of 0.89. Thus, QTc3 was predictive of prolonged QTc interval (Figure 2 ).
DISCUSSION
We have shown that 30% (15 of 50) infants receiving a standard dose (0.8 mg/kg per day) of cisapride developed a prolonged QTc interval during a 14-day study period. Normalization of the QTc interval was noted in 13 of the 15 infants by day 14 despite continued cisapride therapy.
No infant in our study developed clinical deterioration, arrhythmia, or serious adverse effects. The longest QTc interval we observed in any infant was 506 msec. This is consistent with a report that infants (not treated with cisapride) with QTc interval <500 msec had transient prolonged QTc interval and no mortality, whereas only the infants with QTc interval 600 msec demonstrated severe adverse effects (''torsades de pointes,'' second degree A-V block) and mortality. 28 In 1996, cisapride was reported to induce an increase in QTc interval and bradycardia in a neonate. 19 The discontinuation of the drug led to a normalization of the QTc interval. Several subsequent studies (including infants, children, and adults) confirmed cisapride-induced QTc prolongation. 16 -18,30 These studies used various cisapride dosage schedules and reported incidences of QTc interval prolongation of 12% to 31%. Thus, our findings are consistent with previously published data. Levine et al. 20 suggested that there was no cisapride-induced increase in QTc interval when measured at or after 14 days of initiating cisapride. This report is also consistent with our data that show the majority of infants who develop prolonged QTc interval with cisapride return to normal by 14 days of therapy, even when they continued receiving cisapride.
We had expected premature infants to have a higher incidence of prolonged QTc interval with cisapride inversely correlating with gestational age. Because cisapride is metabolized by the cytochrome P-450 3A4 enzyme system, 25 the immaturity of this specific enzyme system may predispose to high plasma concentrations of the drug or its metabolites. We did not find a correlation between prolonged QTc interval during cisapride use and gestational age. Some have reported a correlation between prolonged QTc interval and gestational age, 31 whereas others have not shown one. 20, 21 It is possible that the incidence of cisapride-induced adverse effects in premature infants may be highest during the first few days of life. 32 However, premature infants are seldom receiving more than small enteral feedings in the first few days of life and would typically not be candidates for cisapride therapy.
A baseline ECG is important to evaluate infants for the presence of long QT syndrome. Before the initiation of cisapride it would be desirable to have a reliable predictor of prolonged QTc interval. We were unable to predict prolonged QTc interval from baseline measurements, but did find QTc3 >441 msec to predict prolonged QTc interval at any time in the first 14 days of our study. However, this observation was based on a post hoc analysis and warrants prospective evaluation before it is accepted as a standard. It is reassuring that although 30% of our infants developed prolonged QTc interval, the majority of those infants returned to a normal QTc interval by 14 days of cisapride treatment. None of our infants had arrhythmia.
CONCLUSION
Given the importance of cisapride in the treatment of gastrointestinal dysmotility disorders encountered in premature infants, the challenge is identifying those infants at risk for cisapride-associated morbidity. We have shown that 30% (15 of 50) infants receiving a standard dose (0.8 mg/kg per day) of cisapride developed a prolonged QTc interval during a 14-day study period. Normalization of the QTc interval was noted in 13 of the 15 infants by day 14 despite continued cisapride therapy. QTc interval 3 days following cisapride initiation may assist in identifying infants at risk for QTc interval prolongation. Although cisapride is currently available for infants only as an investigational drug, we propose its use in hospitalized and monitored infants, at an appropriate dose, can provide important benefits with minimal risk. 
